Diabetes Care, Vol 23, Issue 11 1637-1641, Copyright © 2000 by American Diabetes Association
Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes
HP Wetzler and JW Snyder
American Medical Group Association, Bainbridge Island, Washington, USA. hwetz@aol.com
OBJECTIVE: To use pharmacy and laboratory data to assess diabetes care
within a medical group and between medical groups and to determine
dispensing patterns and the extent to which providers change therapy based
on HbA1c results. RESEARCH DESIGN AND METHODS: Participating groups
submitted 1 year of data for continuously enrolled patients. Required data
included date of birth, all diabetes-specific prescriptions (oral
hypoglycemic agents and insulin), date of prescription, National Drug Code,
all HbA1c values, lower and upper normal limits, and date of testing.
RESULTS: Few changes in therapy were noted despite the large percentages of
patients with suboptimal control. Nearly 90% of the patients treated with
medications received a monotherapy regimen involving one of three
therapeutic agents: sulfonylureas, metformin, or insulin. More than
three-fourths of the patients remained on the same therapy during the
observation period despite the fact that 27% of these patients had HbA1c
values > or = 8%. Nearly one-fifth (18%) of patients had an HbA1c level
of > or = 8% and no further testing for at least 90 days after the
"actionable" HbA1C result was obtained. Furthermore, 54% of patients with
actionable HbA1c results did not have a change in therapy initiated after
the result was available. CONCLUSIONS: The American Diabetes Association
recommendations to act on HbA1c values > or = 8% and to follow up
regularly on patients found to be in suboptimal control do not appear to be
applied in a consistent manner based on the pharmacy and laboratory data
analyzed in this sample.